Identification and characterisation of STMN4 and ROBO2 gene involvement in neuroblastoma cell differentiation

Cancer Letters

Volumn 328, Issue 1, 2013, Pages 168-175

  Sung, Pei Ju ^a   Boulos, Nidal ^a   Tilby, Michael John ^a   Andrews, William David ^b   Newbold, Robert Frank ^c   Tweddle, Deborah Anne ^a   Lunec, John ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c BRUNEL UNIVERSITY   (United Kingdom)

Author keywords

MYCN; Neuroblastoma; Neuronal differentiation; ROBO2; STMN4

Indexed keywords

ALITRETINOIN; MESSENGER RNA; ROBO2 PROTEIN; STMN4 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CELL DIFFERENTIATION; CHROMOSOME 1; GENE; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC IDENTIFICATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; MICROARRAY ANALYSIS; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; ROBO2 GENE; STMN4 GENE; UPREGULATION;

CELL DIFFERENTIATION; CELL LINE, TUMOR; GENE EXPRESSION; HUMANS; NERVE GROWTH FACTORS; NEUROBLASTOMA; RECEPTORS, IMMUNOLOGIC; STATHMIN;

EID: 84868459561     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.08.015     Document Type: Article

References (40)

1. Noesel v.M.M., Versteeg R. Pediatric neuroblastomas: genetic and epigenetic 'danse macabre'. Gene 2004, 325:1-15.
2. Maris J.M., Hogarty M.D., Bagatell R., Cohn S.L. Neuroblastoma. Lancet 2007, 369:2106-2120.
3. Shimada H., Ambros I.M., Dehner L.P., Hata J., Joshi V.V., Roald B., Stram D.O., Gerbing R.B., Lukens J.N., Matthay K.K., Castleberry R.P. The international neuroblastoma pathology classification (the Shimada system). Cancer 1999, 86:364-372.
4. Shimada H., Ambros I.M., Dehner L.P., Hata J., Joshi V.V., Roald B. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the international neuroblastoma pathology committee. Cancer 1999, 86:349-363.
5. Ambros I.M., Hata J., Joshi V.V., Roald B., Dehner L.P., Tuchler H., Potschger U., Shimada H. Morphologic features of neuroblastoma (Schwannian stroma-poor tumors) in clinically favorable and unfavorable groups. Cancer 2002, 94:1574-1583.
6. Mohlin S.A., Wigerup C., Pahlman S. Neuroblastoma aggressiveness in relation to sympathetic neuronal differentiation stage. Seminars in Cancer Biology 2011, 21:276-282.
7. Fredlund E., Ringner M., Maris J.M., Pahlman S. High MYC pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:14094-14099.
8. Schwab M., Westermann F., Hero B., Berthold F. Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncology 2003, 4:472-480.
9. Fischer M., Oberthuer A., Brors B., Kahlert Y., Skowron M., Voth H., Warnat P., Ernestus K., Hero B., Berthold F. Differential expression of neuronal genes defines subtypes of disseminated neuroblastoma with favorable and unfavorable outcome. Clinical Cancer Research 2006, 12:5118-5128.
10. Ohira M., Morohashi A., Inuzuka H., Shishikura T., Kawamoto T., Kageyama H., Nakamura Y., Isogai E., Takayasu H., Sakiyama S., Suzuki Y., Sugano S., Goto T., Sato S., Nakagawara A. Expression profiling and characterization of 4200 genes cloned from primary neuroblastomas: identification of 305 genes differentially expressed between favorable and unfavorable subsets. Oncogene 2003, 22:5525-5536.
11. Hoehner J.C., Hedborg F., Eriksson L., Sandstedt B., Grimelius L., Olsen L., Pahlman S. Developmental gene expression of sympathetic nervous system tumors reflects their histogenesis. Laboratory Investigation 1998, 78:29-45.
12. Ohira M., Oba S., Nakamura Y., Isogai E., Kaneko S., Nakagawa A., Hirata T., Kubo H., Goto T., Yamada S., Yoshida Y., Fuchioka M., Ishii S., Nakagawara A. Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas. Cancer Cell 2005, 7:337-350.
13. Fredlund E., Ringnér M., Maris J.M., Påhlman S. High MYC pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:14094-14099.
14. Westermark U.K., Wilhelm M., Frenzel A., Henriksson M.A. The MYCN oncogene and differentiation in neuroblastoma. Seminars in Cancer Biology 2011, 21:256-266.
15. Nara K., Kusafuka T., Yoneda A., Oue T., Sangkhathat S., Fukuzawa M. Silencing of MYCN by RNA interference induces growth inhibition, apoptotic activity and cell differentiation in a neuroblastoma cell line with MYCN amplification. International Journal of Oncology 2007, 30:1189-1196.
16. Kang J.-H., Rychahou P.G., Ishola T.A., Qiao J., Evers B.M., Chung D.H. MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells. Biochemical and Biophysical Research Communications 2006, 351:192-197.
17. Matthay K.K., Villablanca J.G., Seeger R.C., Stram D.O., Harris R.E., Ramsay N.K., Swift P., Shimada H., Black C.T., Brodeur G.M., Gerbing R.B., Reynolds C.P. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. New England Journal of Medicine 1999, 341:1165-1173.
18. Matthay K.K., Reynolds C.P., Seeger R.C., Shimada H., Adkins E.S., Haas-Kogan D., Gerbing R.B., London W.B., Villablanca J.G. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. Journal of Clinical Oncology 2009, 27:1007-1013.
19. Thiele C.J., Reynolds C.P., Israel M.A. Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature 1985, 313:404-406.
20. Bader S.A., Fasching C., Brodeur G.M., Stanbridge E.J. Dissociation of suppression of tumorigenicity and differentiation in vitro effected by transfer of single human chromosomes into human neuroblastoma cells. Cell Growth and Differentiation 1991, 2:245-255.
21. Chu P.W.K., Cheung W.M.W., Kwong Y.L. Differential effects of 9-cis, 13-cis and all-trans retinoic acids on the neuronal differentiation of human neuroblastoma cells. Neuroreport 2003, 14:1935-1939.
22. Lovat P.E., Dobson M., Malcolm A.J., Pearson A.D., Redfern C.P. Differential gene regulation by 9-cis and all-trans retinoic acid in neuroblastoma cells. Medical and Pediatric Oncology 2001, 36:135-138.
23. Grandinetti K.B., Spengler B.A., Biedler J.L., Ross R.A. Loss of one HuD allele on chromosome #1p selects for amplification of the N-myc proto-oncogene in human neuroblastoma cells. Oncogene 2006, 25:706-712.
24. Chen L., Malcolm A.J., Wood K.M., Cole M., Variend S., Cullinane C., Pearson A.D.J., Lunec J., Tweddle D.A. P53 is nuclear and functional in both undifferentiated and differentiated neuroblastoma. Cell Cycle 2007, 6:2685-2696.
25. Pool M., Thiemann J., Bar-Or A., Fournier A.E. NeuriteTracer: a novel ImageJ plugin for automated quantification of neurite outgrowth. Journal of Neuroscience Methods 2008, 168:134-139.
26. Beilharz E.J., Zhukovsky E., Lanahan A.A., Worley P.F., Nikolich K., Goodman L.J. Neuronal activity induction of the stathmin-like gene RB3 in the rat hippocampus: possible role in neuronal plasticity. Journal of Neuroscience 1998, 18:9780-9789.
27. Caron H., Peter M., van Sluis P., Speleman F., de Kraker J., Laureys G., Michon J., Brugieres L., Voute P.A., Westerveld A., et al. Evidence for two tumour suppressor loci on chromosomal bands 1p35-36 involved in neuroblastoma: one probably imprinted, another associated with N-myc amplification. Human Molecular Genetics 1995, 4:535-539.
28. Doherty A.M., Fisher E.M. Microcell-mediated chromosome transfer (MMCT): small cells with huge potential. Mammalian Genome 2003, 14:583-592.
29. Bell E., Premkumar R., Carr J., Lu X., Lovat P.E., Kees U.R., Lunec J., Tweddle D.A. The role of MYCN in the failure of MYCN amplified neuroblastoma cell lines to G1 arrest after DNA damage. Cell Cycle 2006, 5:2639-2647.
30. Jang Y.K., Park J.J., Lee M.C., Yoon B.H., Yang Y.S., Yang S.E., Kim S.U. Retinoic acid-mediated induction of neurons and glial cells from human umbilical cord-derived hematopoietic stem cells. Journal of Neuroscience Research 2004, 75:573-584.
31. Wang L.J., Colella R., Roisen F.J. Ganglioside GM1 alters neuronal morphology by modulating the association of MAP2 with microtubules and actin filaments. Brain Research. Developmental Brain Research 1998, 105:227-239.
32. Bell E., Lunec J., Tweddle D.A. Cell cycle regulation targets of MYCN identified by gene expression microarrays. Cell Cycle 2007, 6:1249-1256.
33. Carr J., Bell E., Pearson A.D.J., Kees U.R., Beris H., Lunec J., Tweddle D.A. Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapse. Cancer Research 2006, 66:2138-2145.
34. Liu Z., Patel K., Schmidt H., Andrews W., Pini A., Sundaresan V. Extracellular Ig domains 1 and 2 of Robo are important for ligand (Slit) binding. Molecular and Cellular Neurosciences 2004, 26:232-240.
35. Carr J., Bown N.P., Case M.C., Hall A.G., Lunec J., Tweddle D.A. High-resolution analysis of allelic imbalance in neuroblastoma cell lines by single nucleotide polymorphism arrays. Cancer Genetics and Cytogenetics 2007, 172:127-138.
36. Lastowska M., Viprey V., Santibanez-Koref M., Wappler I., Peters H., Cullinane C., Roberts P., Hall A.G., Tweddle D.A., Pearson A.D.J., Lewis I., Burchill S.A., Jackson M.S. Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data. Oncogene 2007, 26:7432-7444.
37. Andrews W., Barber M., Hernadez-Miranda L.R., Xian J., Rakic S., Sundaresan V., Rabbitts T.H., Rannell R., Rabbitts P. The role of Slit-Robo signaling in the generation, migration and morphological differentiation of cortical interneurons. Developmental Biology 2008, 313:648-658.
38. Gavet O., El Messari S., Ozon S., Sobel A. Regulation and subcellular localization of the microtubule-destabilizing stathmin family phosphoproteins in cortical neurons. Journal of Neuroscience Research 2002, 68:535-550.
39. Oe T., Sasayama T., Nagashima T., Muramoto M., Yamazaki T., Morikawa N., Okitsu O., Nishimura S., Aoki T., Katayama Y., Kita Y. Differences in gene expression profile among SH-SY5Y neuroblastoma subclones with different neurite outgrowth responses to nerve growth factor. Journal of Neurochemistry 2005, 94:1264-1276.
40. Wei J.S., Greer B.T., Westermann F., Steinberg S.M., Son C.-G., Chen Q.-R., Whiteford C.C., Bilke S., Krasnoselsky A.L., Cenacchi N., Catchpoole D., Berthold F., Schwab M., Khan J. Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer Research 2004, 64:6883-6891. [erratum appears in Cancer Research 2005 January 1;65(1):374].